映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09606 映恩生物-B

休市中 06-12 16:08:21

186.100

+7.000

+3.91%

最高190.200	最低173.400	成交量118.09万
今开180.000	昨收179.100	日振幅9.38%
总市值168.24亿	流通市值168.24亿	总股本9,040万
成交额2.17亿	换手率1.31%	流通股本9,040万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":186.1,"timestamp":1781251701010,"preClose":179.1,"halted":0,"volume":1180879,"delay":0,"changeRate":0.03908431044109436,"floatShares":90401200,"shares":90401200,"eps":-46.109866395016255,"marketStatus":"休市中","change":7,"latestTime":"06-12 16:08:21","open":180,"high":190.2,"low":173.4,"amount":217263220,"amplitude":0.093802,"askPrice":186.2,"askSize":1100,"bidPrice":186.1,"bidSize":5800,"shortable":3,"etf":0,"ttmEps":-36.92496637542608,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":7,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":179.1,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":1.0686097871423514,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606","defaultTab":"news","newsList":[{"id":"2642299848","title":"映恩生物-B(09606)：上交所受理人民币股份发行申请材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2642299848","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642299848?lang=zh_cn&edition=full","pubTime":"2026-06-12 22:30","pubTimestamp":1781274625,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，公司已向上海证券交易所提交有关人民币股份发行的申请材料，其中包括首次公开发行人民币普通股(A股)并在科创板上市招股说明书(申报稿)，并已于近期收到上海证券交易所就公司提交的人民币股份发行申请出具的受理单。A股招股说明书将刊载于上海证券交易所网站(http://www.sse.com.cn)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CNHmain","HK0000500386.USD","LU2543165471.USD","CYB","MCNHmain","MUCmain","HK0000252152.HKD","HK0000252160.HKD","09606","BK1161","UCmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121144905","title":"异动解读｜映恩生物-B盘中下跌5.61%，生物科技板块集体承压回购难挡抛售潮","url":"https://stock-news.laohu8.com/highlight/detail?id=1121144905","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121144905?lang=zh_cn&edition=full","pubTime":"2026-06-11 10:36","pubTimestamp":1781145365,"startTime":"0","endTime":"0","summary":"6月11日，映恩生物-B盘中下跌5.61%，报166.6港元/股，成交额3620.53万港元。消息面上，公司虽于6月10日公告科创板IPO辅导通过上海证监局验收，并持续实施回购，但未能扭转股价颓势。此前公司凭借ASCO临床数据催化于6月5日一度反弹逾6%，但反弹昙花一现，股价自高点持续回落。生物科技板块今日集体走弱，百济神州跌5.71%、科伦博泰生物跌4.68%、康方生物跌4.43%、三生制药跌3.82%、信达生物跌3.09%，板块系统性抛压加剧个股调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158692458","title":"映恩生物-B于6月10日回购1万股，涉资约167.42万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158692458","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158692458?lang=zh_cn&edition=full","pubTime":"2026-06-10 22:16","pubTimestamp":1781101013,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年6月10日发布翌日披露报表。公告显示，公司于2026年6月8日至6月10日期间因非董事人员根据首次公开发行前股权激励计划行使购股权，累计发行普通股32,300股，分别对应发行价格为每股178.0741港元、171.746港元及166.0608港元；此次新增发行股份总量合计占前次已发行股本约0.0357%。根据公告，截至2026年6月10日收市后，公司已发行股份总数为90,401,214股，库藏股数量为272,400股，合计已发行股份及库藏股数量为90,673,614股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物-B于6月10日回购1万股，涉资约167.42万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642557424","title":"映恩生物-B(09606)6月10日斥资167.4万港元回购1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642557424","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642557424?lang=zh_cn&edition=full","pubTime":"2026-06-10 22:13","pubTimestamp":1781100818,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，于2026年6月10日斥资167.4万港元回购1万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","BK1161","LU2543165471.USD","09606","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642428704","title":"DualityBio Ltd.增持映恩生物-B(09606)1万股 每股作价173.778港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642428704","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642428704?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:51","pubTimestamp":1781088687,"startTime":"0","endTime":"0","summary":"6月9日，DualityBio Ltd.增持映恩生物-B(09606)1万股，每股作价173.778港元，总金额为173.778万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260610/20260610185214_27442.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260610/20260610185214_27442.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","LU2543165471.USD","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","09606","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642413960","title":"映恩生物-B(09606.HK)：就建议人民币股份于科创板上市通过上海监管局辅导验收","url":"https://stock-news.laohu8.com/highlight/detail?id=2642413960","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642413960?lang=zh_cn&edition=full","pubTime":"2026-06-10 07:07","pubTimestamp":1781046422,"startTime":"0","endTime":"0","summary":"格隆汇6月10日丨映恩生物-B(09606.HK)发布公告，有关拟发行将于上交所科创板上市并以人民币买卖的普通股(“建议上市”)。公司现正接受中信证券的辅导，而公司已就有关辅导通过中国证监会上海监管局的验收。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260610/32274856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["CYB","IPOS","HK0000500386.USD","MUCmain","159982","BK1161","09606","HK0000252152.HKD","MCNHmain","UCmain","LU2543165471.USD","HK0000252160.HKD","CNHmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150501392","title":"映恩生物-B获上海证监局辅导备案受理 拟推进人民币股份上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1150501392","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150501392?lang=zh_cn&edition=full","pubTime":"2026-06-10 06:22","pubTimestamp":1781043736,"startTime":"0","endTime":"0","summary":"映恩生物-B（Duality Biotherapeutics）已获得中国证监会上海监管局的辅导备案受理，此举标志着公司拟议的人民币股份上市计划迈出了关键一步。\n接受辅导备案是企业在境内资本市场进行首次公开募股前的必要程序。这意味着公司已正式启动上市辅导流程，将依照监管要求，在保荐机构的协助下，进行公司治理、财务规范等方面的完善工作，为后续提交上市申请做准备。\n此举被视为映恩生物-B拓展融资渠道、深化本土市场布局的重要战略举措。人民币股份上市若成功实施，将有助于公司进一步融入中国资本市场，为其生物医药技术的研发与商业化提供更充足的资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","HK0000500386.USD","BK1161","09606","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173838925","title":"异动解读｜映恩生物-B盘中下跌5.25%，ASCO反弹昙花一现回购力度难抵抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1173838925","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173838925?lang=zh_cn&edition=full","pubTime":"2026-06-08 11:25","pubTimestamp":1780889138,"startTime":"0","endTime":"0","summary":"6月8日，映恩生物-B盘中下跌5.25%，报176.8港元/股，成交额5288.32万港元。此前公司凭借连续回购及ASCO临床数据催化于6月5日一度反弹逾6%，但反弹未能延续。映恩生物是一家临床阶段生物制药公司，致力于研发抗体偶联药物创新药物，主要候选产品包括DB-1303/BNT323、DB-1311/BNT324等，用于靶向治疗多种实体瘤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135490971","title":"映恩生物-B：6月5日回购7,000股并发行9,300股","url":"https://stock-news.laohu8.com/highlight/detail?id=1135490971","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135490971?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:52","pubTimestamp":1780660347,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年6月5日发布翌日披露报表，公告显示，公司于当日回购7,000股普通股，并将该等股份转为库存股份。此次回购股份占变动前已发行股份的0.0077%，每股价格介乎192.6港元至198.1港元，总金额1,372,080港元。本次变动后，映恩生物-B已发行股份增至90,378,914股，库存股份增至262,400股，总发行股份为90,641,314股。公司于2025年6月20日通过回购授权，可购回最多8,803,626股公司股份，截至目前累计回购股份数为262,400股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B：6月5日回购7,000股并发行9,300股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641117008","title":"映恩生物-B(09606)6月5日斥资137.21万港元回购7000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641117008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641117008?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:45","pubTimestamp":1780659949,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，于2026年6月5日斥资137.21万港元回购7000股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606","HK0000252152.HKD","HK0000252160.HKD","BK1161","HK0000500386.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163285803","title":"异动解读｜映恩生物-B盘中上涨6.03%，持续回购叠加ASCO临床数据催化反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1163285803","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163285803?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:50","pubTimestamp":1780624252,"startTime":"0","endTime":"0","summary":"6月5日，映恩生物-B盘中上涨6.03%，报195.0港元，成交额5777.75万港元。消息面上，公司近日密集实施股份回购，6月2日至4日连续三日分别回购6.45万股、3.71万股及3.4万股，合计耗资约2723万港元。同时，公司于6月4日公告拟授权回购不超过已发行股份总数10%的股份，进一步释放护盘信号。生物科技板块今日整体走强，科伦博泰生物涨5.13%、信达生物涨3.53%、康方生物涨2.36%，板块情绪共振提振个股表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148636421","title":"映恩生物-B拟回购不超过已发行股份总数10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148636421","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148636421?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:41","pubTimestamp":1780584106,"startTime":"0","endTime":"0","summary":"映恩生物-B发布公告，董事会建议授予一般授权，用于回购不超过截至股东特别决议案通过之日本公司已发行股本总数10%的股份。按公告披露，若公司已发行股份及库藏股维持不变，则回购规模可达9,037,661股。公告显示，映恩生物-B将于2026年6月26日（星期五）上午9时30分在中国上海市浦东新区樱花路868号A座11楼董事会会议室召开股东周年大会，就回购及其他相关授权议案作出审议表决。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B拟回购不超过已发行股份总数10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185411689","title":"映恩生物-B回购34,000股股份，耗资约645.58万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185411689","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185411689?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:41","pubTimestamp":1780573316,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年6月4日发布公告，披露当日于香港联交所场内回购34,000股普通股，占回购前已发行股本约0.0376%，每股回购价介乎港币186.3元至201.8元，合计耗资约6,455,750港元。公告显示，此次回购依据公司于2025年6月20日通过的购回授权开展，授权总数为8,803,626股。公司确认，其回购已遵守香港联合交易所有限公司证券上市规则等相关法律和规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B回购34,000股股份，耗资约645.58万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640035154","title":"映恩生物-B(09606)6月4日斥资645.58万港元回购3.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640035154","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640035154?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:38","pubTimestamp":1780573120,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，于2026年6月4日斥资645.58万港元回购3.4万股;根据于2021年2月28日获采纳并于2023年6月25日修订的首次公开发售前股权激励计划，行使所授予的购股权而发行1.01万股普通股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","09606","LU2543165471.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135490481","title":"异动解读｜映恩生物-B盘中下跌5.04%，报190.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135490481","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135490481?lang=zh_cn&edition=full","pubTime":"2026-06-04 10:35","pubTimestamp":1780540553,"startTime":"0","endTime":"0","summary":"6月4日，映恩生物-B盘中下跌5.04%，报190.1港元/股，成交额8159.41万港元。映恩生物-B所在的生物科技行业中，板块整体承压，个股中，康方生物跌3.85%，百济神州涨1.88%，信达生物跌1.11%，三生制药跌3.0%，荣昌生物跌1.43%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324等，用于靶向治疗多种实体瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101831523","title":"映恩生物-B6月3日回购3.71万股股份，总额约748.74万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101831523","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101831523?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:16","pubTimestamp":1780488977,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年6月3日发布公告，披露公司当日在香港联交所场内回购37,100股普通股，占当日回购前公司已发行股本的约0.041%。回购价格介乎每股199.6港元至205.4港元，合共付出约748.74万港元。根据公告，映恩生物-B董事亦于同日根据2021年2月28日采纳并于2023年6月25日修订的首次公开发售前股权激励计划行使购股权，发行8,800股普通股，占公司已发行股本的约0.0097%，发行价为每股201.7114港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B6月3日回购3.71万股股份，总额约748.74万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640945857","title":"映恩生物-B(09606)6月2日斥资1329.8万港元回购6.45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640945857","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640945857?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:01","pubTimestamp":1780405315,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，该公司于2026年6月2日斥资1329.8万港元回购6.45万股股份，每股回购价格为198.1-209.4港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","09606","HK0000500386.USD","HK0000252160.HKD","BK1161","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180537116","title":"映恩生物-B回购6.45万股股份，涉资约1,329.80万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180537116","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180537116?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:01","pubTimestamp":1780405270,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年6月2日发布公告显示，2026年6月2日该公司在香港联交所回购64,500股普通股，占回购前已发行股本约0.0713%，每股成交量加权平均价格为206.1712港元，最高回购价为209.4港元，最低回购价为198.1港元，总金额约13,298,040港元。本次回购后，公司库存股增至184,300股，已发行股本为90,428,814股，合计已发行股本数目为90,613,114股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B回购6.45万股股份，涉资约1,329.80万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1126348696","title":"映恩生物-B2026年5月股份变动月报表，股本略有增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1126348696","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126348696?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:56","pubTimestamp":1780404960,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年6月2日发布2026年5月股份变动月报表。报告期内，公司注册股本为2亿股普通股，每股面值0.0001美元，注册股本金额维持在2万美元，与上月一致。根据月报显示，映恩生物-B在5月内因行使“首次公开发售前股权激励计划”而发行了167,600股新股，同时注销了12,498份期权，最终导致相关期权存量减少至18,450,530份。上述回购后，这些股份被列作库存股份持有。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187714473","title":"异动解读｜映恩生物-B盘中下跌5.59%，报213.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187714473","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187714473?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:07","pubTimestamp":1780283268,"startTime":"0","endTime":"0","summary":"6月1日，映恩生物-B盘中下跌5.59%，报213.0港元/股，成交额1.52亿港元。映恩生物-B所在的生物科技行业中，板块表现分化，个股中，康方生物涨2.37%，三生制药涨1.14%，信达生物跌2.64%，百济神州跌2.32%，科伦博泰生物跌3.25%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324等，用于靶向治疗多种实体瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":-0.0027},{"period":"1month","weight":-0.2435},{"period":"3month","weight":-0.3118},{"period":"6month","weight":-0.4295},{"period":"1year","weight":-0.3354},{"period":"ytd","weight":-0.3759}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}